ECG Immunitor is a next-generation biotech company pioneering the oral form of antisense oligonucleotide (ASO) technology. Under the flagship brand Immugence, we offer modified DNA lock-and-key platform that precisely targets a wide range of conditions—including non-communicable diseases (NCDs), infectious diseases, neurological disorders, and mental illnesses—with a focus on enhancing longevity and painless solution for patients. With over 60 ready-to-commercialize ASO products, our pipeline addresses some of the world’s most critical health burdens, such as cancer, HIV, stroke, Alzheimer’s, Parkinson’s, Thalassemia, and chronic infections. The technology delivers rapid, measurable outcomes while being completely non-toxic and painless—a significant leap forward from conventional treatment options.